Recce Pharmaceuticals Ltd

Recce Pharmaceuticals Ltd is a publicly listed biotechnology company specializing in the development of a pioneering class of synthetic anti-infective therapies. Its primary mission is to address the escalating global health threat posed by antibiotic-resistant superbugs and difficult-to-treat bacterial infections. The company has introduced anti-infectives with a unique universal mechanism of action designed to maintain potency against bacteria and viruses, even with repeated use—a significant advancement compared to traditional antibiotics, whose effectiveness often diminishes over time due to cellular mutation and resistance. Recce Pharmaceuticals is actively progressing multiple drug candidates through clinical phases, including registrational trials, targeting major unmet needs in infectious disease management. Founded in 2007 by Dr Graham Melrose, a renowned figure in pharmaceutical research, the company operates from Sydney, Australia, and leverages the expertise of a dedicated research and management team. With recognition from regulatory bodies like the FDA and inclusion on global priority lists, Recce Pharmaceuticals plays an important role in the pharmaceuticals and biotech sector, aiming to reshape how bacterial infections are managed worldwide.